The meta-analysis revealed a positive trend across trials, suggesting that while the benefits regarding mortality may differ across trials, the overall effect of the class on the combined outcome of HHF and cardiovascular death remains stable.
← all excerpts
Heart Failure Outcomes with SGLT2 Inhibitors in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
1
—
—